Fintepla Access Update: What Patients Need to Know in 2026

If you're searching for a Fintepla shortage update, here's what you need to know: as of 2026, Fintepla (fenfluramine) is not listed on the FDA's official drug shortage database. The access challenges patients experience are not due to manufacturing problems or supply chain disruptions — they stem from a tightly controlled restricted distribution system required by federal law.

That said, for families dealing with rare, treatment-resistant epilepsy, these barriers can feel just as disruptive as a supply shortage. This update explains the current landscape and what has changed.

Is Fintepla in a Shortage in 2026?

No. Fintepla is not currently listed on the FDA's Drug Shortage Database. UCB, which acquired Fintepla from Zogenix in 2022, continues to manufacture and supply it. There are no public reports of manufacturing disruptions or supply constraints as of early 2026.

The reason many patients have difficulty accessing Fintepla is the FINTEPLA REMS (Risk Evaluation and Mitigation Strategy) program — a federal safety requirement that restricts dispensing to certified specialty pharmacies only.

What Has Changed for Fintepla in Recent Years?

Several important developments have shaped the current Fintepla landscape:

2020: FDA approves Fintepla for Dravet syndrome (DS) in patients 2 years and older — the first approval.

2022: FDA expands approval to cover Lennox-Gastaut syndrome (LGS). UCB acquires Fintepla from Zogenix, bringing greater resources to patient support programs.

2025: Final analysis of the long-term open-label extension study (published in Epilepsia) confirmed sustained seizure reduction with no cases of valvular heart disease or pulmonary arterial hypertension observed over multiple years of treatment.

2026: Fintepla continues to be available exclusively through REMS-certified specialty pharmacies. No generic version is currently available.

Why the Long-Term Safety Data Matters for Patients

One of the biggest concerns families have about Fintepla is its boxed warning for valvular heart disease and pulmonary arterial hypertension — a risk inherited from fenfluramine's history as a weight-loss drug in the 1990s.

The good news: in clinical trials for Dravet syndrome and LGS lasting up to 3 years, no patients developed valvular heart disease or pulmonary arterial hypertension. The 2025 long-term extension study published in Epilepsia confirmed these findings over an even longer follow-up period. The most common treatment-related adverse events were pyrexia (fever), nasopharyngitis (upper respiratory infection), and decreased appetite — all manageable side effects.

This accumulating safety data is reassuring for families weighing the benefits and risks of Fintepla.

What Access Barriers Do Patients Still Face in 2026?

Despite the absence of a manufacturing shortage, real-world access remains challenging for some patients. The main barriers as of 2026 include:

REMS enrollment delays: Both prescribers and pharmacies must be enrolled before a prescription can be filled. New prescribers can face delays.

Insurance prior authorization: Most plans require PA, which takes 30-45 days on average. Denials are common on first submission.

Echocardiogram coordination: Patients must complete a baseline echocardiogram before starting. Scheduling and completing this test adds time.

Specialty pharmacy logistics: Mail-order delivery means planning ahead. Running out mid-cycle is a risk without good refill management.

Is a Generic Fintepla Available?

No. As of 2026, Fintepla is only available as a brand-name medication. There is no FDA-approved generic fenfluramine oral solution. The product was granted Orphan Drug Designation and pediatric exclusivity, which extends the exclusivity period. Patients should not attempt to use non-pharmaceutical fenfluramine products, which lack the safety monitoring infrastructure of the REMS program.

Practical Steps for Patients Having Trouble Getting Fintepla

1. Confirm your prescriber is REMS-certified (call 1-877-964-3649 to check)

2. Contact UCB's ONWARD support team (1-833-463-7547) to initiate insurance assistance

3. Schedule the baseline echocardiogram — this must be done before your first dose

4. Ask your neurologist to submit a detailed PA request with seizure logs and prior drug failure history

5. [@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop to quickly identify which certified specialty pharmacies can fill your prescription

If you are still facing an extended delay, talk to your neurologist about bridging with another approved therapy. Read: Alternatives to Fintepla if you can't fill your prescription.